Patents by Inventor Thomas Trieselmann

Thomas Trieselmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20240109909
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 4, 2024
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11731981
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: August 22, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors
    Patent number: 11583532
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11319310
    Abstract: The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 3, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11254688
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220002310
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 6, 2022
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 11136337
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11046706
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • BENZYL-, (PYRIDIN-3-YL)METHYL -OR (PYRIDIN-4-YL)-METHYL-SUBSTIITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210053985
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 25, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • PYRAZOLE- AND INDAZOLE- SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210040113
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Viktor VINTONYAK
  • TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210038603
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • HETEROCYCLYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
    Publication number: 20210040077
    Abstract: The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Viktor VINTONYAK
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20190300541
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 3, 2019
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 10308667
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • CCR2 receptor antagonists and uses thereof
    Patent number: 10196402
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 5, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Oxadiazolopyridine Derivatives for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors
    Publication number: 20180251476
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 6, 2018
    Inventors: Cédrickx GODBOUT, Thomas TRIESELMANN, Viktor VINTONYAK
  • Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: 9994591
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: June 12, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors
    Publication number: 20180037594
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 8, 2018
    Inventors: Cédrickx GODBOUT, Thomas TRIESELMANN, Viktor VINTONYAK
  • NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20170362249
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 21, 2017
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
    Patent number: RE49446
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak